Quoin Pharmaceuticals shares surge 11.30% intraday after FDA grants Fast Track to QRX003 for Netherton Syndrome.

Quoin Pharmaceuticals (NASDAQ: QNRX) surged 11.30% intraday after the U.S. Food and Drug Administration granted Fast Track Designation to its lead candidate, QRX003 lotion (4%), for the treatment of Netherton Syndrome. This regulatory milestone follows prior Orphan Drug and Pediatric Rare Disease designations from the FDA and the European Medicines Agency, underscoring the therapy’s potential to address a severe, untreatable genetic skin disorder. Fast Track status enables expedited regulatory communication and accelerated approval pathways, which could streamline Quoin’s development timeline for the first approved treatment for Netherton Syndrome. The news reinforced investor confidence in the company’s ability to advance its pipeline for rare diseases, with QRX003 currently in two late-stage clinical trials. The announcement aligns with the stock’s sharp intraday rally, reflecting optimism over regulatory progress and the drug’s commercial potential.